IDH1 and IDH2 Mutations in Gliomas

Cited by (1,012)

Items 801–900 of 1,012

1. The Temporal Order of Genetic and Pathway Alterations in Tumorigenesis
   Moritz Gerstung, Nicholas Eriksson, Jimmy Lin, Bert Vogelstein, Niko Beerenwinkel · 2011 · PLoS ONE
2. Metabolic dysregulation in monogenic disorders and cancer — finding method in madness
   Erez, Ayelet, DeBerardinis, Ralph J. · 2015 · Nature Reviews Cancer
3. microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-β Signaling in Glioblastoma
   Giannicola Genovese, Ayla Ergün, Sachet Ashok Shukla, Benito Campos, Jason A. Hanna, Papia Ghosh, Steven N. Quayle, Kunal Rai, Simona Colla, Haoqiang Ying et al. · 2012 · Cancer Discovery
4. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
   Luyuan Li, Ana Cristina Paz, Breelyn Ann Wilky, Britt A. Johnson, Karina A. Galoian, Andrew Eric Rosenberg, Guozhi Hu, Gabriel Tinoco, Olaf A. Bodamer, Jonathan C. Trent · 2015 · PLoS ONE
5. An epigenetic gateway to brain tumor cell identity
   Stephen C. Mack, Christopher G. Hubert, Tyler E. Miller, Michael D. Taylor, Jeremy N. Rich · 2015 · Nature Neuroscience
6. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration
   Paul A. Clark, Saswati Bhattacharya, Ardem Elmayan, Soesiawati R. Darjatmoko, Bradley A. Thuro, Michael B. Yan, Paul R. van Ginkel, Arthur S. Polans, John S. Kuo · 2016 · Journal of neurosurgery
7. An Update on Neurofibromatosis Type 1-Associated Gliomas
   Mina Lobbous, Joshua D. Bernstock, Elizabeth Coffee, Gregory K. Friedman, Laura K. Metrock, Gustavo Chagoya, Galal Elsayed, Ichiro Nakano, James R. Hackney, Bruce R. Korf et al. · 2020 · Cancers
8. Targeting Glutamine Addiction in Gliomas
   Marta Obara‐Michlewska, Monika Szeliga · 2020 · Cancers
9. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation
   Ruichao Chai, Yao-Wu Zhang, Yuqing Liu, Yuzhou Chang, Bo Pang, Tao Jiang, Wenqing Jia, Yongzhi Wang · 2020 · Acta Neuropathologica Communications
10. Moving pan-cancer studies from basic research toward the clinic
    Feng Chen, Michael C. Wendl, Matthew A. Wyczalkowski, Matthew H. Bailey, Yize Li, Li Ding · 2021 · Nature Cancer
11. Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP+/NADPH ratio
    Momoe Itsumi, Satoshi Inoue, Andrew Elia, K Murakami, Masato Sasaki, Evan F. Lind, Dirk Brenner, Isaac S. Harris, Iok In Christine Chio, S Afzal et al. · 2015 · Cell Death and Differentiation
12. Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations
    Darcy A. Kerr, Hector U. Lopez, Vikram Deshpande, Francis John Hornicek, Zhenfeng Duan, Yaxia Zhang, Andrew Eric Rosenberg, Darrel R. Borger, G. Petur Nielsen · 2013 · The American Journal of Surgical Pathology
13. Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?
    Martin C. Tom, Daniel P. Cahill, Jan C. Buckner, Jörg Dietrich, Michael W. Parsons, Jennifer S. Yu · 2019 · American Society of Clinical Oncology Educational Book
14. Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging
    Madeleine Shaver, Paul A. Kohanteb, Catherine Chiou, Michelle D. Bardis, Chanon Chantaduly, Daniela Annenelie Bota, Christopher G. Filippi, Brent D. Weinberg, Jack Grinband, Daniel S. Chow et al. · 2019 · Cancers
15. In Situ Sprayed Starvation/Chemodynamic Therapeutic Gel for Post‐Surgical Treatment of IDH1 (R132H) Glioma
    Chunying Li, Yilin Wan, Yifan Zhang, Lian‐Hua Fu, Nicholas Thomas Blum, Run Cui, Boda Wu, Rui Zheng, Jing Lin, Zhiming Li et al. · 2021 · Advanced Materials
16. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging
    Seunghyun Lee, Seung Hong Choi, Inseon Ryoo, Tae Jin Yoon, Tae Min Kim, Se‐Hoon Lee, Chul‐Kee Park, Ji‐hoon Kim, Chul‐Ho Sohn, Sung‐Hye Park et al. · 2014 · Journal of Neuro-Oncology
17. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas
    Samantha Messina, Luigi Frati, Carlo Leonetti, Candida Zuchegna, Erika Di Zazzo, Antonella Calogero, Antonio Porcellini · 2011 · Oncogene
18. Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
    Elizabeth R. Lawlor, Carol J. Thiele · 2012 · Clinical Cancer Research
19. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
    Tor-Christian Aase Johannessen, Joydeep Mukherjee, Pavithra Viswanath, Shigeo Ohba, Sabrina M. Ronen, Rolf Bjerkvig, Russell O. Pieper · 2016 · Molecular Cancer Research
20. Independent prognostic variables in acute myeloid leukaemia
    Matthew L. Smith, Robert Kerrin Hills, David J. Grimwade · 2010 · Blood Reviews
21. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III
    Michela Visani, Dario de Biase, Gianluca Marucci, Serenella Cerasoli, Evandro Nigrisoli, Maria Letizia Bacchi Reggiani, Fiorenzo Albani, Agostino Baruzzi, Annalisa Pession, the PERNO study group · 2013 · Molecular Oncology
22. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio M. P. Omuro, Timothy An-thy Chan, Lauren E. Abrey, Mustafa Khasraw, Anne S. Reiner, Thomas Joseph Kaley, Lisa Marie DeAngelis, Andrew B. Lassman, Craig P. Nolan, Igor T. Gavrilovic et al. · 2012 · Neuro-Oncology
23. Unravelling tumour heterogeneity—implications for therapy
    David A. Reardon, Patrick Yung Wen · 2015 · Nature Reviews Clinical Oncology
24. Taming the dragon: genomic biomarkers to individualize the treatment of cancer
    Ian J. Majewski, René Bernards · 2011 · Nature Medicine
25. Cancer cell metabolism and the modulating effects of nitric oxide
    Ching-Fang Chang, Anne R. Diers, Neil Hogg · 2014 · Free Radical Biology and Medicine
26. EPMA position paper in cancer: current overview and future perspectives
    Godfrey Grech, Xianquan Zhan, Byong Chul Yoo, Rostyslav V Bubnov, Suzanne Hagan, Romano Danesi, Giorgio Vittadini, Dominic M. Desiderio · 2015 · The EPMA Journal
27. Machine learning classifies cancer
    Derek Wong, Stephen S. F. Yip · 2018 · Nature
28. Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs
    Anton A. Buzdin, Maxim Sorokin, Andrew Garazha, Marina I Sekacheva, Ella L. Kim, Nikolay V. Zhukov, Ye Wang, Xinmin Li, Souvik Kar, Christian Johannes Hartmann et al. · 2018 · Seminars in Cancer Biology
29. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States
    Quinn T. Ostrom, Madison L Shoaf, Gino Cioffi, Kristin A. Waite, Carol A. Kruchko, Patrick Yung Wen, Daniel Jay Brat, Jill S. Barnholtz‐Sloan, Julian Bryan Iorgulescu · 2022 · Neuro-Oncology
30. IDH inhibition in gliomas: from preclinical models to clinical trials
    Roberta Rudà, Craig Horbinski, Martin J. van den Bent, Matthias Preusser, Riccardo Soffietti · 2024 · Nature Reviews Neurology
31. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
    Johnny Suijker, Jan Oosting, Annemarie Koornneef, Eduard A. Struys, Gajja Sophi Salomons, Frank G. Schaap, Cathelijn J. F. Waaijer, Pauline M. Wijers‐Koster, Inge H. Briaire‐de Bruijn, Lizette C. J. M. Haazen et al. · 2015 · Oncotarget
32. Mutational landscape of AML with normal cytogenetics: Biological and clinical implications
    Maria Paola Martelli, Paolo Sportoletti, Enrico Tiacci, Massimo F. Martelli, Brunangelo Falini · 2012 · Blood Reviews
33. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival
    Pattana Wangaryattawanich, Masumeh Hatami, Jixin Wang, Ginu A. Thomas, Adam Eugene Flanders, Justin Kirby, Max Wintermark, Erich S. Huang, Ali Bakhtiari, Markus Martin Luedi et al. · 2015 · Neuro-Oncology
34. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy
    Mark Vitucci, David Neil Hayes, C. Ryan Miller · 2010 · British Journal of Cancer
35. Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment
    Ching-Ann Liu, Chia‐Yu Chang, Kuo-Wei Hsueh, Hong-Lin Su, Tzyy‐Wen Chiou, Shinn‐Zong Lin, Horng‐Jyh Harn · 2018 · International Journal of Molecular Sciences
36. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
    Sherise Desiree Ferguson, Shouhao Zhou, Jason T. Huse, John de Groot, Joanne Xiu, Deepa Suresh Subramaniam, Shwetal V. Mehta, Zoran Gatalica, Jeffrey J. Swensen, Nader Sanai et al. · 2018 · Journal of Neuropathology & Experimental Neurology
37. Blockade of Glutathione Metabolism in IDH1 -Mutated Glioma
    Xiaoying Tang, Xiao Fu, Yang Liu, Di Yu, Sabrina J. Cai, Chunzhang Yang · 2019 · Molecular Cancer Therapeutics
38. Deep semi-supervised learning for brain tumor classification
    Chenjie Ge, Irene Yu‐Hua Gu, Asgeir Store Jakola, Jie Yang · 2020 · BMC Medical Imaging
39. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients
    Satoshi Nakamizo, Takashi Sasayama, Masakazu Shinohara, Yasuhiro Irino, Shin Nishiumi, Masamitsu Nishihara, Hirotomo Tanaka, Kazuhiro Tanaka, Katsu Mizukawa, Tomoo Itoh et al. · 2013 · Journal of Neuro-Oncology
40. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas
    Jantima Tanboon, Erik Abraham Williams, David N. Louis · 2015 · Journal of Neuropathology & Experimental Neurology
41. Epigenetic Regulation of the miR142-3p/Interleukin-6 Circuit in Glioblastoma
    Guang‐Yuh Chiou, Chian‐Shiu Chien, Mong‐Lien Wang, Ming-Teh Chen, Yi‐Ping Yang, Yung‐Luen Yu, Yueh Chien, Yun‐Ching Chang, Chiung‐Chyi Shen, Chung‐Ching Chio et al. · 2013 · Molecular Cell
42. Modulation of HJURP (Holliday Junction-Recognizing Protein) Levels Is Correlated with Glioblastoma Cells Survival
    Valéria Valente, Rodolfo Bortolozo Serafim, Leonardo Cesar de Oliveira, Fernando Soares Adorni, Raul Torrieri, Daniela Pretti da Cunha Tirapelli, Enilza Maria Espreáfico, Sueli Mieko Oba‐Shinjo, Suely Kazue Nagahashi Marie, Maria Luisa Paçó‐Larson et al. · 2013 · PLoS ONE
43. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome
    Jiang Lin, Dong‐ming Yao, Jun Qian, Qin Chen, Wei Qian, Yun Li, Jing Chun Yang, Cui‐zhu Wang, Hai‐yan Chai, Zhen Yu Qian et al. · 2011 · Annals of Hematology
44. Immunotherapy for Brain Cancer: Recent Progress and Future Promise
    Christopher Mitchell Jackson, Michael K. Lim, Charles G. Drake · 2014 · Clinical Cancer Research
45. Automated MRI based pipeline for segmentation and prediction of grade, IDH mutation and 1p19q co-deletion in glioma
    Milan Decuyper, Stijn Bonte, Karel Deblaere, Roel Van Holen · 2020 · Computerized Medical Imaging and Graphics
46. Human Brat Ortholog TRIM3 Is a Tumor Suppressor That Regulates Asymmetric Cell Division in Glioblastoma
    Gang Chen, Jun Kong, Carol Tucker‐Burden, Monika Anand, Yuan Rong, Fahmia Rahman, Carlos S. Moreno, Erwin G. Van Meir, Constantinos G. Hadjipanayis, Daniel Jay Brat · 2014 · Cancer Research
47. Applications of metabolomics in cancer research
    Mark P. Styczynski, Kathleen A. Vermeersch · 2013 · Journal of Carcinogenesis
48. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas
    Doris Helbig, Michaela A. Ihle, Katharina Pütz, Iliana Tantcheva‐Poór, Cornelia Mauch, Reinhard Büttner, Alexander Quaas · 2016 · Oncotarget
49. Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1
    Vidya Rajendran · 2016 · Molecular BioSystems
50. Sequencing Structural Variants in Cancer for Precision Therapeutics
    Geoff Macintyre, Bauke Ylstra, James D. Brenton · 2016 · Trends in Genetics
51. CircFOXO3 promotes glioblastoma progression by acting as a competing endogenous RNA for NFAT5
    Shuai Zhang, Keman Liao, Zengli Miao, Qing Wang, Yifeng Miao, Zhongye Guo, Yun Qiu, Binghong Chen, Li Ren, Zilong Wei et al. · 2019 · Neuro-Oncology
52. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors
    Andrew Jeffrey Dunbar, Kelly L. Bolton, Sean M. Devlin, Francisco Sánchez-Vega, Jianjiong Gao, Jodi Victoria Mones, Jonathan Wills, Daniel Kelly, Mirko Farina, Keith B. Cordner et al. · 2020 · Blood
53. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
    Manali Tilak, Jennifer Holborn, Laura A. New, Jasmin Lalonde, Nina Jones · 2021 · International Journal of Molecular Sciences
54. Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours.
    I. Blümcke, S. Budday, A. Poduri, Dennis Lal, K. Kobow, S. Baulac · 2021 · Lancet Neurology
55. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors
    Marta Mellai, Angela Piazzi, Valentina Caldera, Oriana Monzeglio, Paola Cassoni, Guido Valente, Davide Schiffer · 2011 · Journal of Neuro-Oncology
56. Glioblastoma stem cells
    Ghazaleh Tabatabai, Michael Weller · 2011 · Cell and Tissue Research
57. Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
    Aizhen Liu, Chunfeng Hou, Hongfang Chen, Xuan Zong, Peijun Zong · 2016 · Frontiers in Oncology
58. High-grade Gliomas
    Lakshmi Nayak, David A. Reardon · 2017 · CONTINUUM Lifelong Learning in Neurology
59. Unraveling the Genetics of Cancer: Genome Sequencing and Beyond
    Kit Man Wong, Thomas J. Hudson, John D. McPherson · 2011 · Annual Review of Genomics and Human Genetics
60. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study
    Phoenix A. Ho, Todd A. Alonzo, Kenneth J. Kopecky, K L Miller, J Kuhn, R Zeng, Robert B. Gerbing, S Raimondi, Betsy A Hirsch, Vivian G. Oehler et al. · 2010 · Leukemia
61. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival
    Pengfei Wang, Hongwang Song, Hong‐Qing Cai, Ling-Wei Kong, Kun Yao, Tao Jiang, Shouwei Li, Changxiang Yan · 2017 · Oncotarget
62. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1 -Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity
    Kensuke Tateishi, Fumi Higuchi, Julie J. Miller, Mara V.A. Koerner, Nina Lelic, Ganesh M. Shankar, Shota Tanaka, David E. Fisher, Tracy T. Batchelor, Anthony John Iafrate et al. · 2017 · Cancer Research
63. The existence of a nonclassical TCA cycle in the nucleus that wires the metabolic-epigenetic circuitry
    Liu, Xujun, Si, Wenzhe, He, Lin, Yang, Jianguo, Peng, Yani, Ren, Jie, Liu, Xiaoping, Jin, Tong, Yu, Huajing, Zhang, Zihan et al. · 2021 · Signal Transduction and Targeted Therapy
64. C IC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas
    Vincent Gleize, Agustí Alentorn, Léa Connen de Kérillis, Marianne Labussière, Aravindan Arun Nadaradjane, Emeline Mundwiller, Chris Ottolenghi, Stephanie Mangesius, Amithys Rahimian, François Ducray et al. · 2015 · Annals of Neurology
65. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA
    Yingyu Sun, Wei Zhang, Dongfeng Chen, Yu-Hong Lv, Junxiong Zheng, Henrik Lilljebjörn, Ran Liang, Zhaoshi Bao, Charlotte Soneson, Hans Olov Sjögren et al. · 2014 · Proceedings of the National Academy of Sciences
66. The mitochondrial side of epigenetics
    Alessandra Castegna, Vito Iacobazzi, Vittoria Infantino · 2015 · Physiological Genomics
67. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing
    Daniel Baumhoer, Fernanda M Amary, Adrienne Margaret Flanagan · 2018 · Genes Chromosomes and Cancer
68. Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas
    Shuang Wu, Jin Meng, Qi Yu, Ping Li, Shen Fu · 2019 · Journal of Cancer Research and Clinical Oncology
69. Glutamine Metabolism in Brain Tumors
    Siva Kumar Natarajan, Sriram Venneti · 2019 · Cancers
70. Epidemiology, risk factors, and prognostic factors of gliomas
    Alessia Pellerino, Mario Caccese, Marta Padovan, Giulia Cerretti, Giuseppe Lombardi · 2022 · Clinical and Translational Imaging
71. Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation
    Anastasia Spyropoulou, Antonios N. Gargalionis, Georgia Dalagiorgou, Christos Adamopoulos, Kostas A. Papavassiliou, Robert William Lea, Christina Piperi, Athanasios G. Papavassiliou · 2013 · NeuroMolecular Medicine
72. The role of 5-hydroxymethylcytosine in development, aging and age-related diseases.
    Virginia López, A. Fernández, M. Fraga · 2017 · Ageing Research Reviews
73. 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
    Leonie I. Kroeze, Bert A. van der Reijden, Joop H. Jansen · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
74. Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis
    Daniel Richard Wahl, Joseph Dresser, Kari Wilder-Romans, Joshua D. Parsels, Shuang George Zhao, Mary A. Davis, Lili Zhao, Maureen T. Kachman, Stefanie Wernisch, Charles Burant et al. · 2016 · Cancer Research
75. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis
    Javier E. Villanueva-Meyer, Matthew D. Wood, Byung Se Choi, Marc C. Mabray, Nicholas Arthur Butowski, Tarık Tihan, Soonmee Cha · 2017 · American Journal of Roentgenology
76. Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress
    Susan J. Gelman, Fuad J. Naser, Nathaniel G. Mahieu, Lisa D. McKenzie, Gavin P. Dunn, Milan G. Chheda, Gary J. Patti · 2018 · Cell Reports
77. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients
    Daniel Paech, Constantin Dreher, Sebastian Regnery, Jan‐Eric Meissner, Steffen Goerke, Johannes Windschuh, Johanna Oberhollenzer, Miriam N. Schultheiss, Katerina Deike‐Hofmann, Sebastian Bickelhaupt et al. · 2019 · European Radiology
78. The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
    Houda Abla, Manuela Sollazzo, Giuseppe Gasparre, Luisa Iommarini, Anna Maria Porcelli · 2019 · Seminars in Cell and Developmental Biology
79. The current state of immunotherapy for gliomas: an eye toward the future
    Peter Edward Fecci, John Howard Sampson · 2019 · Journal of neurosurgery
80. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
    Remco Jurriaan Molenaar, Swapna Thota, Yasunobu Nagata, Bhumika J. Patel, Michael J. Clemente, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Aaron D. Viny, N Hosano, Fonnet E. Bleeker et al. · 2015 · Leukemia
81. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009
    Dorothee Gramatzki, Silvia Dehler, Elisabeth Jane Rushing, Kathrin Zaugg, Silvia Höfer, Yasuhiro Yonekawa, Helmut Bertalanffy, Anton Valavanis, Dimitri Korol, Sabine Rohrmann et al. · 2016 · Cancer
82. Metabolomics in Drug Target Discovery
    Joshua D. Rabinowitz, John G. Purdy, Livia Vastag, Thomas E. Shenk, Emre Koyuncu · 2011 · Cold Spring Harbor Symposia on Quantitative Biology
83. Benefits of interferon‐β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter
    Kazuya Motomura, Atsushi Natsume, Yugo Kishida, Hiroyuki Higashi, Yutaka Kondo, Yoko Nakasu, Tatsuya Abé, Hiroki Namba, Kenji Wakai, Toshihiko Wakabayashi · 2010 · Cancer
84. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study
    Elles J. T. M. van der Louw, Joanne F. Olieman, Patricia M. L. A. van den Bemt, Jacoline E. C. Bromberg, Esther Oomen‐de Hoop, Rinze Frederik Neuteboom, Coriene E. Catsman‐Berrevoets, Arnaud J.P.E. Vincent · 2019 · Therapeutic Advances in Medical Oncology
85. Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma
    Guo Gord Zhu, Khédoudja Nafa, Narasimhan P. Agaram, Ahmet Zehir, Ryma Benayed, Justyna Sadowska, Laetitia A Borsu, Ciara Marie Kelly, William D. Tap, Nicola Fabbri et al. · 2019 · Clinical Cancer Research
86. A basic review on systemic treatment options in WHO grade II-III gliomas
    Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna Sophie Berghoff · 2020 · Cancer Treatment Reviews
87. Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution
    Zhaoshi Bao, Yongzhi Wang, Qiangwei Wang, Shengyu Fang, Xia Shan, Jiguang Wang, Tao Jiang · 2021 · Frontiers of Medicine
88. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification
    Hengrui Liu, Tao Tang · 2023 · Scientific Reports
89. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
    Daniel Krell, Mawuelikem Assoku, Malcolm Galloway, Paul James Mulholland, Ian P.M. Tomlinson, Chiara Bardella · 2011 · PLoS ONE
90. IDH1 and IDH2 mutations in pediatric acute leukemia
    Anna Andersson, D W Miller, J A Lynch, Andrew S. Lemoff, Zhongling Cai, Stanley B Pounds, Ina Radtke, Bing Yan, John D. Schuetz, Jeffrey E. Rubnitz et al. · 2011 · Leukemia
91. Oligodendroglioma cell lines containing t(1;19)(q10;p10)
    John J. Kelly, Michael D. Blough, Owen D.M. Stechishin, Jennifer Ai-wen Chan, Daniel R. Beauchamp, Marco Perizzolo, Douglas J. Demetrick, L. Steele, Roland N. Auer, Walter J Hader et al. · 2010 · Neuro-Oncology
92. Molecular Epidemiology of Primary Brain Tumors
    Jun Gu, Yanhong Liu, Athanassios P. Kyritsis, Melissa L. Bondy · 2009 · Neurotherapeutics
93. Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1
    Mindy I. Davis, Stefan Größ, Min Shen, Kimberly S. Straley, Rajan Pragani, Wendy Lea, Janeta V. Popovici-Müller, Byron DeLaBarre, Erin Artin, Natasha Thorne et al. · 2014 · Journal of Biological Chemistry
94. Nicotinamide Nucleotide Transhydrogenase (Nnt) Links the Substrate Requirement in Brain Mitochondria for Hydrogen Peroxide Removal to the Thioredoxin/Peroxiredoxin (Trx/Prx) System
    Pamela Lopert, Manisha Patel · 2014 · Journal of Biological Chemistry
95. Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
    Xiaowei Guan, Jaime E. Vengoechea, Siyuan Zheng, Andrew Edward Sloan, Yanwen Chen, Daniel Jay Brat, Brian Patrick O’Neill, John de Groot, Shlomit Yust‐Katz, Wai-Kwan Alfred Yung et al. · 2014 · PLoS ONE
96. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
    Benedikt Wiestler, Rainer Claus, S. A. Hartlieb, Maximilian G. Schliesser, Elisa K. Weiß, Thomas Hielscher, Michael Platten, L M Dittmann, Christoph Meisner, Jörg Felsberg et al. · 2013 · Neuro-Oncology
97. A chemical probe toolbox for dissecting the cancer epigenome
    Jake Shortt, Christopher J. Ott, Ricky W. Johnstone, James E. Bradner · 2017 · Nature reviews. Cancer
98. Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma
    Chia-Hung Chien, Wei‐Ting Hsueh, Jian‐Ying Chuang, Kwang‐Yu Chang · 2021 · Journal of Biomedical Science
99. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy
    Mahmoud S. Alghamri, Brandon L. McClellan, Ruthvik Avvari, Rohit Thalla, Stephen V. Carney, Carson S. Hartlage, Santiago Haase, Maria Ventosa, Ayman W. Taher, Neha Kamran et al. · 2021 · Science Advances
100. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
     Natsume, Atsushi, Arakawa, Yoshiki, Narita, Yoshitaka, Sugiyama, Kazuhiko, Hata, Nobuhiro, Muragaki, Yoshihiro, Shinojima, Naoki, Kumabe, Toshihiro, Saito, Ryuta, Motomura, Kazuya et al. · 2023 · Neuro-Oncology